IVBT Innovation1 Biotech Inc (CE)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Directors

The board of directors (the “Board”) of the Company elected and appointed, effective December 5, 2022, Charles W. Allen and Shahin Gharakhanian, MD, DTM&H, DPH to serve on the Board as directors in such capacity until their successor is appointed and qualified or until their earlier resignation or removal.

Charles W. Allen, age 47. Since February 5, 2014 Mr. Allen has served as the CEO of BTCS Inc. (“BTCS”) and the Chairman of the Board of BTCS since September 11, 2014. Mr. Allen is responsible for our overall corporate strategy and direction of BTCS. Since January 12, 2018 Mr. Allen has been the CEO of Global Bit Ventures Inc. (“GBV”), which discontinued its operations in 2019. From October 10, 2017, Mr. Allen has been a director of GBV. Mr. Allen has extensive experience in business strategy and structuring and executing a variety of investment banking and capital markets transactions, including financings, IPO’s and mergers and acquisitions. Prior to his work in the blockchain industry at BTCS he worked domestically and internationally on projects in technology, media, natural resources, logistics, medical services and financial services. He has served as a Managing Director at numerous boutique investment banks focused on advising and raising capital for small and mid-size companies. Mr. Allen received a B.S. in Mechanical Engineering from Lehigh University and a M.B.A. from the Mason School of Business at the College of William & Mary. The Board concludes that Mr. Allen’s professional background and leadership experience qualify him to serve on the board.

Shahin Gharakhanian, MD, DTM&H, DPH, age 68. Dr. Gharakhanian is Chair, Scientific Advisory Board of Decoy Therapeutics.  Dr. Gharakhanian is a Physician-Executive with expertise in Pharmaceutical Medicine, Leadership/Management, and an international track record: Clinical Medicine, Attending Physician, Infectious Diseases & Tropical Medicine @ AP-HP Assistance Publique–Hopitux de Paris, the largest hospital system in Europe. He has worked closely with HIV discoverers 2008 Nobel Laureate, Françoise Barré-Sinoussi and HIV co-discoverer Willy Rozenbaum (Science, 1981). Dr. Gharakhanian has held industry positions, including Vice-President of Vertex Pharmaceuticals Inc., Global R&D group in Cambridge MA, Corporate Operating Council Member. He oversaw clinical and launch of four novel treatments including a “blockbuster” in chronic HCV.  In 2011, Dr. Gharakhanian founded Shahin Gharakhanian MD Consulting LLC @ the CIC: Cambridge Innovation Center, an elite consulting network providing strategic/operational expertise in drug development. Collaborations globally include >20 companies, eg. Genzyme Corp. (USA), GSK/ViiV Healthcare (USA), Novartis (Switzerland/USA), Stallergenes Greer (France/USA). Dr. Gharakhanian’s medical education has been at Paris-Sorbonne University with documented two decades at Harvard Medical School Programs. His academic or industry work has been comprised of: Bacterial disease (ds): Clostridium Difficile, Microbiomes, Tuberculosis; Viral ds: HIV, HBV, HCV, RSV; Parasitic ds: Malaria.